HOWL official logo HOWL
HOWL 1-star rating from Upturn Advisory
Werewolf Therapeutics Inc (HOWL) company logo

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL) 1-star rating from Upturn Advisory
$0.95
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: HOWL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

2 star rating from financial analysts

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $6.17

1 Year Target Price $6.17

Analysts Price Target For last 52 week
$6.17 Target price
52w Low $0.6
Current$0.95
52w High $2.38

Analysis of Past Performance

Type Stock
Historic Profit -29.47%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 46.20M USD
Price to earnings Ratio -
1Y Target Price 6.17
Price to earnings Ratio -
1Y Target Price 6.17
Volume (30-day avg) 6
Beta 0.74
52 Weeks Range 0.59 - 2.38
Updated Date 12/6/2025
52 Weeks Range 0.59 - 2.38
Updated Date 12/6/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.62

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-11-06
When -
Estimate -0.388
Actual -0.36

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -40.75%
Return on Equity (TTM) -122.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 16100363
Price to Sales(TTM) 52.22
Enterprise Value 16100363
Price to Sales(TTM) 52.22
Enterprise Value to Revenue 0.67
Enterprise Value to EBITDA 0.57
Shares Outstanding 48540200
Shares Floating 35938679
Shares Outstanding 48540200
Shares Floating 35938679
Percent Insiders 5.61
Percent Institutions 44.94

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Werewolf Therapeutics Inc

Werewolf Therapeutics Inc(HOWL) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Werewolf Therapeutics, Inc. is a biopharmaceutical company founded in 2017. It focuses on developing conditionally activated therapeutics engineered to stimulate the immune system for the treatment of cancer. The company has advanced its pipeline of novel INDUKINE molecules, aiming to provide targeted and effective cancer therapies.

Company business area logo Core Business Areas

  • Novel INDUKINE Molecules: Werewolf Therapeutics develops novel INDUKINE molecules that are designed to selectively activate the immune system within the tumor microenvironment, thus minimizing systemic toxicity and maximizing anti-tumor efficacy.
  • Preclinical and Clinical Development: The company is involved in preclinical research, IND-enabling studies, and clinical trials to advance its pipeline of INDUKINE molecules through the various stages of drug development.

leadership logo Leadership and Structure

The leadership team includes experienced professionals in drug development, oncology, and biopharmaceutical management. The company operates with a structure conducive to research, development, and clinical operations, with a focus on innovation and scientific excellence.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • WTX-124: WTX-124 is Werewolf's lead product candidate, a conditionally activated IL-2 INDUKINE molecule targeting solid tumors. It is currently in Phase 1 clinical trials. There are other IL-2 therapeutics in the market, such as Proleukin (aldesleukin) from Clinigen, but WTX-124 aims to offer improved safety and tolerability via conditional activation.
  • WTX-330: WTX-330 is a conditionally activated IL-12 INDUKINE molecule. It is in preclinical development. Competitors are developing IL-12 therapies, such as those from Bristol Myers Squibb and other pharmaceutical companies, but Werewolf aims to provide improved targeting and reduced systemic toxicity.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is focused on developing innovative therapies for cancer. This includes immuno-oncology approaches to activate the immune system against cancer cells. The industry is characterized by high R&D spending, stringent regulatory requirements, and potential for significant returns on successful products.

Positioning

Werewolf Therapeutics is positioned as an innovator in the immuno-oncology space, leveraging its INDUKINE platform to develop conditionally activated therapeutics. Its competitive advantage lies in the potential for improved safety, tolerability, and efficacy compared to traditional cytokine therapies.

Total Addressable Market (TAM)

The global oncology market is estimated to be hundreds of billions of dollars. Werewolf is focused on a specific segment within this market, involving cytokine-based therapies. Successful development and commercialization of its INDUKINE molecules could capture a significant portion of this segment.

Upturn SWOT Analysis

Strengths

  • Novel INDUKINE platform
  • Experienced leadership team
  • Focus on targeted immuno-oncology
  • Strong intellectual property position

Weaknesses

  • Early stage of development (clinical trials)
  • Reliance on preclinical and clinical data
  • High R&D costs
  • Limited commercialization experience

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion of INDUKINE platform to other targets
  • Regulatory approvals and commercialization

Threats

  • Clinical trial failures
  • Competition from other immuno-oncology therapies
  • Regulatory hurdles
  • Financial risks and funding challenges

Competitors and Market Share

Key competitor logo Key Competitors

  • BMRN
  • NKTR
  • ALKS

Competitive Landscape

Werewolf Therapeutics competes with other immuno-oncology companies developing cytokine therapies and other cancer treatments. Its advantage is the targeted approach of its INDUKINE platform, while its disadvantage is being in the earlier stages of development compared to some competitors.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is measured by progress in the clinic and pipeline advancements, rather than revenue. These advancements influence investor sentiment and stock valuation.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and potential commercialization or partnerships. Analyst estimates are needed for specific financial projections.

Recent Initiatives: Recent initiatives include advancing WTX-124 through Phase 1 trials, preclinical development of WTX-330, and exploring potential new INDUKINE targets.

Summary

Werewolf Therapeutics is a clinical-stage biopharmaceutical company with a promising INDUKINE platform. Positive early clinical data are key to driving growth and attracting partnerships. The company needs to manage its cash burn and navigate regulatory hurdles. Competition within the immuno-oncology space is strong.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Werewolf Therapeutics Inc

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2021-04-30
Founder, CEO, President, Secretary & Director Dr. Daniel J. Hicklin Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 39
Full time employees 39

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.